Indian pharmaceutical units face a severe crisis. Input costs have surged by 200-300 percent. This is due to global conflicts disrupting ra...

India’s pharmaceutical industry is facing the risk of medicine shortages as a propane gas crunch forces several manufacturing units to part...

India's medicine prices are poised for a sharp increase due to a 30% surge in raw material costs, driven by container ship scarcity followi...

Indian medicines may become more affordable as China's active pharmaceutical ingredient (API) prices have dropped significantly, by 35-40%....

Beginning April 1, prices for essential drugs like painkillers, antibiotics, and anti-diabetic medicines will rise by 1.74%. The increase i...

IOL Chemicals share price: IOL Chemicals proposed stock split is subject to shareholder approval via a postal ballot. The record date to de...

IOL Chemicals has approved a 1:5 stock split. This will increase affordability and liquidity. Shareholders will receive 5 new shares for ev...

"We have seen a sharp rise in the sales of drugs like paracetamol, analgesics and drugs for respiratory illnesses," said Rajiv Singhal, gen...

The sharp increase has been witnessed in high-volume key antibiotics including azithromycin and amoxicillin imported from China. "These are...

Key APIs have become 12-25% costlier in the past few days amid possible supply disruptions that may squeeze margins and raise drug prices, ...

According to doctors, as the Covid-19 cases start to increase, people start taking immunity boosters as a precautionary measure, as they se...

The National Pharmaceutical Pricing Authority and the Drug Controller General of India held a meeting with AIOCD on Monday regarding the av...

The lobby group asked to allow prices of all scheduled formulations to be increased by 10% with immediate effect. Scheduled drugs are those...

Two anti-virals — Remdesivir and Favipiravir — and Tocilizumab injections being used in the Covid-19 treatment have witnessed massive short...

Indian pharmaceutical companies source almost 70% of their requirement of Covid-19-related APIs from China. Demand for Covid-19-related med...

. The brokerage expects ~25 per cent/~23 per cent revenue/PAT CAGRs over FY20-22.

The investor relations team at Granules India denied the promoters are seeking to sell their stake.